These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

710 related articles for article (PubMed ID: 23635789)

  • 1. Cancer stem cells in the development of liver cancer.
    Yamashita T; Wang XW
    J Clin Invest; 2013 May; 123(5):1911-8. PubMed ID: 23635789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of liver cancer stem cells and clinical correlations.
    Cheng Z; Li X; Ding J
    Cancer Lett; 2016 Sep; 379(2):230-8. PubMed ID: 26272183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orchestration of hepatocellular carcinoma development by diverse liver cancer stem cells.
    Yamashita T; Kaneko S
    J Gastroenterol; 2014 Jul; 49(7):1105-10. PubMed ID: 24647548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The evolving concept of liver cancer stem cells.
    Nio K; Yamashita T; Kaneko S
    Mol Cancer; 2017 Jan; 16(1):4. PubMed ID: 28137313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Musashi 2 contributes to the stemness and chemoresistance of liver cancer stem cells via LIN28A activation.
    Fang T; Lv H; Wu F; Wang C; Li T; Lv G; Tang L; Guo L; Tang S; Cao D; Wu M; Yang W; Wang H
    Cancer Lett; 2017 Jan; 384():50-59. PubMed ID: 27721018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel therapeutic strategies for targeting liver cancer stem cells.
    Oishi N; Wang XW
    Int J Biol Sci; 2011 Apr; 7(5):517-35. PubMed ID: 21552419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway.
    Huang WC; Tung SL; Chen YL; Chen PM; Chu PY
    BMC Cancer; 2018 May; 18(1):609. PubMed ID: 29848298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Granulin-epithelin precursor is an oncofetal protein defining hepatic cancer stem cells.
    Cheung PF; Cheng CK; Wong NC; Ho JC; Yip CW; Lui VC; Cheung AN; Fan ST; Cheung ST
    PLoS One; 2011; 6(12):e28246. PubMed ID: 22194816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipopolysaccharide supports maintaining the stemness of CD133(+) hepatoma cells through activation of the NF-κB/HIF-1α pathway.
    Lai FB; Liu WT; Jing YY; Yu GF; Han ZP; Yang X; Zeng JX; Zhang HJ; Shi RY; Li XY; Pan XR; Li R; Zhao QD; Wu MC; Zhang P; Liu JF; Wei LX
    Cancer Lett; 2016 Aug; 378(2):131-41. PubMed ID: 27208741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway.
    Li B; Cao Y; Meng G; Qian L; Xu T; Yan C; Luo O; Wang S; Wei J; Ding Y; Yu D
    EBioMedicine; 2019 Jan; 39():239-254. PubMed ID: 30555042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver cancer stem cells: implications for a new therapeutic target.
    Lee TK; Castilho A; Ma S; Ng IO
    Liver Int; 2009 Aug; 29(7):955-65. PubMed ID: 19490415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positive Feedback Loop of OCT4 and c-JUN Expedites Cancer Stemness in Liver Cancer.
    Kuo KK; Lee KT; Chen KK; Yang YH; Lin YC; Tsai MH; Wuputra K; Lee YL; Ku CC; Miyoshi H; Nakamura Y; Saito S; Wu CC; Chai CY; Eckner R; Steve Lin CL; Wang SS; Wu DC; Lin CS; Yokoyama KK
    Stem Cells; 2016 Nov; 34(11):2613-2624. PubMed ID: 27341307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implications of cancer stem cell biology in hepatocellular carcinoma.
    Ji J; Wang XW
    Semin Oncol; 2012 Aug; 39(4):461-72. PubMed ID: 22846863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver cancer stem cell markers: Progression and therapeutic implications.
    Sun JH; Luo Q; Liu LL; Song GB
    World J Gastroenterol; 2016 Apr; 22(13):3547-57. PubMed ID: 27053846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types.
    Holczbauer Á; Factor VM; Andersen JB; Marquardt JU; Kleiner DE; Raggi C; Kitade M; Seo D; Akita H; Durkin ME; Thorgeirsson SS
    Gastroenterology; 2013 Jul; 145(1):221-231. PubMed ID: 23523670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and characterization of tumorigenic liver cancer stem/progenitor cells.
    Ma S; Chan KW; Hu L; Lee TK; Wo JY; Ng IO; Zheng BJ; Guan XY
    Gastroenterology; 2007 Jun; 132(7):2542-56. PubMed ID: 17570225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver cancer stem cells as a hierarchical society: yes or no?
    Gu Y; Zheng X; Ji J
    Acta Biochim Biophys Sin (Shanghai); 2020 Jul; 52(7):723-735. PubMed ID: 32490517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogene-specific formation of chemoresistant murine hepatic cancer stem cells.
    Chow EK; Fan LL; Chen X; Bishop JM
    Hepatology; 2012 Oct; 56(4):1331-41. PubMed ID: 22505225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Smad inhibitor induces CSC differentiation for effective chemosensitization in cyclin D1- and TGF-β/Smad-regulated liver cancer stem cell-like cells.
    Xia W; Lo CM; Poon RYC; Cheung TT; Chan ACY; Chen L; Yang S; Tsao GSW; Wang XQ
    Oncotarget; 2017 Jun; 8(24):38811-38824. PubMed ID: 28415588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BORIS up-regulates OCT4 via histone methylation to promote cancer stem cell-like properties in human liver cancer cells.
    Liu Q; Chen K; Liu Z; Huang Y; Zhao R; Wei L; Yu X; He J; Liu J; Qi J; Qin Y; Li B
    Cancer Lett; 2017 Sep; 403():165-174. PubMed ID: 28645561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.